Review Article
Therapeutic Targeting of Fibroblast Growth Factor Receptors in Gastric Cancer
Table 1
FGFR protein expressions on immunohistochemical analysis and clinical outcomes in GC.
| ā | | Definition of positivity | Positive case % | Relation to clinicopathological factors | Relation to survival | Reference |
| FGFR1 | 222 | Scoring system of intensity + extensity | 29 | T, N, M, stage | Worse | [19] |
| FGFR2 | 950 | 2+ or 3+, >50% | 31 | T, N, M, stage | Worse | [22] | 222 | Scoring system of intensity + extensity | 51 | T, N, M, stage | Worse | [19] | 136 | Stronger than normal epithelium | 31 | T, peritoneal Dissemination, diffuse type | Worse | [20] | 49 | Stronger than normal epithelium | 41 | Stage Undifferentiated type | Worse | [21] |
| FGFR3 | 222 | Scoring system of intensity + extensity | 64 | NA | NA | [19] |
| FGFR4 | 222 | Scoring system of intensity + extensity score | 79 | T, N, M, stage | Worse | [19] | 94 | 3+, >10% | 38 | NA | Worse | [23] |
|
|
T: tumor depth; N: lymph-node metastasis; M: distant metastasis; NA: not assisted.
|